ATRO, the Association for Transitional Research in Oncology was formed in August 2012. It comprises of a team of multidisciplinary specialties including oncologists, basic science researchers, fellows, nurses, nurse practitioners and allied therapists. It was formed with the sole aim of promoting transitional research in the oncology community. This association deliberates debates and engages in meaningful research to build evidence for a personalised care approach to oncology.
Translational research is part of a unidirectional continuum in which research findings are moved from the researcher's bench to the patient's bedside, and then to the community. In the continuum, the first stage of translational research (T1) transfers knowledge from basic research to clinical research. The second stage (T2) transfers findings from clinical studies or clinical trials, to practice settings and communities where the findings improve health. Currently, cancer treatment is guided primarily through a population-based approach by clinical trials that have helped formulate standard cancer treatment guidelines. However, in certain situations, cancer treatment designed for a patient depends upon the type of cancer, clinical picture and the individual patient. The evidence for this personalised care approach in oncology is mounting globally. At present, we are in a transition period from a population-based approach to a personalised care approach. This is the reason we adopt the term 'Translational Research'. The primary objective of the research is to build evidence that quickens the transition period and makes cancer treatment a personalised experience.